Payment overview · 2025
General Payments
$209.25
12 reported records · 8 companies
Healthcare provider profile · identity verified
Kenneth M Spiller, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAFAYETTE, LA · NPI 1043220239
Verified facts
What the public records show
CMS Open Payments records show Kenneth M Spiller, MD received $209.25 in general payments during 2025 across 12 reported records.
Dexcom, Inc. accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess, Mounjaro, Ozempic.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $41.24 | 19.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.99 | 19.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $31.93 | 15.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $28.86 | 13.8% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $18.57 | 8.9% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $18.23 | 8.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.78 | 7.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.65 | 6.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $209.25 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $41.24 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $18.57 | 1 | 2025 |
Source payment records
|
|||||
| Linzess Normalized: linzess |
Drug | IRONWOOD PHARMACEUTICALS, INC | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.18 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.78 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.75 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Linzess linzess |
2025 | Linzess | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 404 | 76 |
| Atorvastatin Calcium | Atorvastatin Calcium | 367 | 90 |
| Alprazolam | Alprazolam | 310 | 60 |
| Amlodipine Besylate | Amlodipine Besylate | 259 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 241 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 194 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 173 | 31 |
| Prednisone | Prednisone | 166 | 90 |
| Lisinopril | Lisinopril | 165 | 35 |
| Gabapentin | Gabapentin | 163 | 35 |
| Lorazepam | Lorazepam | 149 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 145 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 137 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 134 | 32 |
| Omeprazole | Omeprazole | 134 | 30 |
| Losartan Potassium | Losartan Potassium | 122 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 119 | 22 |
| Metformin Hcl | Metformin Hcl | 115 | 25 |
| Glimepiride | Glimepiride | 111 | 21 |
| Tramadol Hcl | Tramadol Hcl | 110 | 32 |
| Trazodone Hcl | Trazodone Hcl | 110 | 23 |
| Potassium Chloride | Potassium Chloride | 108 | 21 |
| Furosemide | Furosemide | 105 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 104 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 96 | 27 |
| Meloxicam | Meloxicam | 91 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 91 | 30 |
| Allopurinol | Allopurinol | 84 | 20 |
| Atenolol | Atenolol | 77 | 14 |
| Diazepam | Diazepam | 76 | suppressed |
| Eliquis | Apixaban | 73 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 72 | 17 |
| Benazepril Hcl | Benazepril Hcl | 63 | 16 |
| Trulicity | Dulaglutide | 62 | suppressed |
| Levofloxacin | Levofloxacin | 58 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 16 |
| Montelukast Sodium | Montelukast Sodium | 57 | 13 |
| Simvastatin | Simvastatin | 57 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | 13 |
| Carvedilol | Carvedilol | 54 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 16 |
| Baclofen | Baclofen | 51 | suppressed |
| Celecoxib | Celecoxib | 51 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 27 |
| Meclizine Hcl | Meclizine Hcl | 51 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 49 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | suppressed |
| Valsartan | Valsartan | 46 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 44 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 44 | suppressed |
| Synthroid | Levothyroxine Sodium | 44 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 42 | suppressed |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 41 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 41 | 11 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Metolazone | Metolazone | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Digoxin | Digoxin | 36 | suppressed |
| Famotidine | Famotidine | 36 | 13 |
| Methylprednisolone | Methylprednisolone | 35 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 25 |
| Finasteride | Finasteride | 33 | suppressed |
| Perindopril Erbumine | Perindopril Erbumine | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 31 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 27 | 16 |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 12 |
| Ozempic | Semaglutide | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 21 |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 22 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 14 |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Armour Thyroid | Thyroid,pork | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Acyclovir | Acyclovir | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Humulin R | Insulin Regular, Human | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Nadolol | Nadolol | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | 11 |
| Triazolam | Triazolam | 14 | suppressed |
| Clomid | Clomiphene Citrate | 13 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Veozah | Fezolinetant | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Perphenazine | Perphenazine | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $209.25 · 12 records | Dexcom, Inc. | AIRSUPRA, Dexcom G6 Transmitter, FARXIGA, IBSRELA, JARDIANCE, Kerendia, Linzess, MOUNJARO, Ozempic, VOQUEZNA, Wegovy, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with IRONWOOD PHARMACEUTICALS, INC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error